Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

J Cancer 2018; 9(2):269-274. doi:10.7150/jca.21774 This issue Cite

Research Paper

A single nucleotide polymorphism in CYP1B1 leads to differential prostate cancer risk and telomere length

Cheng-Yuan Gu1,2*, Gao-Xiang Li1,2*, Yu Zhu1,2, Hua Xu1,2, Yao Zhu1,2, Xiao-Jian Qin1,2, Dai Bo1,2✉, Ding-Wei Ye1,2✉

1. Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China;
2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
* These authors contributed equally to this work.

✉ Corresponding authors: Bo Dai (bodai1978com) and Ding-Wei Ye (dwyelicom), Department of Urology, Fudan University Shanghai Cancer Center, No. 270 Dong'an Road, Shanghai 200032, People's Republic of China. Tel: 86-21-64175590-2807; Fax: 86- More

Citation:
Gu CY, Li GX, Zhu Y, Xu H, Zhu Y, Qin XJ, Bo D, Ye DW. A single nucleotide polymorphism in CYP1B1 leads to differential prostate cancer risk and telomere length. J Cancer 2018; 9(2):269-274. doi:10.7150/jca.21774. https://www.jcancer.org/v09p0269.htm
Other styles

File import instruction

Abstract

BACKGROUND: Cytochrome P450 1B1 (CYP1B1) is a key enzyme in its oestrogen metabolism pathway, giving rise to hydroxylation and conjugation. Functionally relevant genetic variants within CYP1B1 may affect the telomere length and subsequently lead to prostate carcinogenesis.

METHODS: We evaluated 8 CYP1B1 tag single nucleotide polymorphisms (SNPs) in 1015 men with prostate cancer (PCa) and 1052 cancer-free controls, and calculated odds ratios (ORs) and 95% confidence intervals (CIs) to estimate their association with risk of PCa. The influence of CYP1B1 SNPs on the relative telomere lengths was then appraised in peripheral blood leukocytes using real-time PCR.

RESULTS: CYP1B1 rs1056836 variant was associated with decreased risk of PCa [odds ratio (OR): 0.80; 95% confidence interval (CI): 0.68-0.99, P = 0.041]. Longer telomere length showed a significantly higher proportion of the CYP1B1 rs1056836 CG/GG genotypes, compared with that of the CC genotype (OR: 1.60, 95% CI: 1.04-2.45).

CONCLUSION: Our findings suggest that genetic variants within CYP1B1 may confer genetic susceptibility to PCa by altering telomere length.

Keywords: CYP1B1, prostate cancer, single nucleotide polymorphism, susceptibility.

Citation styles

APA
Gu, C.Y., Li, G.X., Zhu, Y., Xu, H., Zhu, Y., Qin, X.J., Bo, D., Ye, D.W. (2018). A single nucleotide polymorphism in CYP1B1 leads to differential prostate cancer risk and telomere length. Journal of Cancer, 9(2), 269-274. https://doi.org/10.7150/jca.21774.

ACS
Gu, C.Y.; Li, G.X.; Zhu, Y.; Xu, H.; Zhu, Y.; Qin, X.J.; Bo, D.; Ye, D.W. A single nucleotide polymorphism in CYP1B1 leads to differential prostate cancer risk and telomere length. J. Cancer 2018, 9 (2), 269-274. DOI: 10.7150/jca.21774.

NLM
Gu CY, Li GX, Zhu Y, Xu H, Zhu Y, Qin XJ, Bo D, Ye DW. A single nucleotide polymorphism in CYP1B1 leads to differential prostate cancer risk and telomere length. J Cancer 2018; 9(2):269-274. doi:10.7150/jca.21774. https://www.jcancer.org/v09p0269.htm

CSE
Gu CY, Li GX, Zhu Y, Xu H, Zhu Y, Qin XJ, Bo D, Ye DW. 2018. A single nucleotide polymorphism in CYP1B1 leads to differential prostate cancer risk and telomere length. J Cancer. 9(2):269-274.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use